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Catheter-based sympathetic renal denervation (RDN) is a recent therapeutic option for
patients with resistant hypertension. However, the impact of RDN in left ventricular (LV)
mass and function is not completely established. Our aim was to evaluate the effects of
RDN on LV structure and function (systolic and diastolic) in patients with resistant hyperten-
sion (HTN).
Methods and Results
From a single centre prospective registry including 65 consecutive patients with resistant
HTN submitted to RDN between July-2011 and April-2015, 31 patients with baseline and 1-
year follow-up echocardiogram were included in this analysis. Mean age was 65±7 years,
48% were males, 71% had type 2 diabetes. Most had hypertension lasting for more than 10
years (90%), and were being treated with a median number of 6 anti-hypertensive drugs,
including 74% on spironolactone. At 1-year, there was a significant decrease both on office
SBP (176±24 to 149±13mmHg, p<0.001) and DBP (90±14 to 79±11mmHg, p<0.001),
and also in 24h ABPM SBP (150±20 to 132±14mmhg, p<0.001) and DBP (83±10 to 74
±9mmHg, p<0.001). There was also a significant decrease in LV mass from 152±32 to 136
±34g/m2 (p<0.001), an increase in LV end diastolic volume (93±18 to 111±27 mL, p =
0.004), an increase in LV ejection fraction (65±9 to 68±9%, p = 0.001) and mitral valve E
deceleration time (225±49 to 247±51ms, p = 0.015) at 1-year follow up. There were no sig-
nificant changes in left atrium volume index or in the distribution of patients among the differ-
ent left ventricle geometric patterns and diastolic function subgroups.
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Conclusions
In this single centre registry of patients with resistant hypertension, renal denervation was
associated with significant reduction in both office and ABPM blood pressure and a significant
decrease in left ventricle mass evaluated by transthoracic echocardiogram at 1 year follow-up.
Introduction
Long-standing hypertension (HTN) results in cardiac remodelling including myocardial
hypertrophy, diastolic dysfunction and left atrial (LA) enlargement leading to atrial and ven-
tricular arrhythmias, heart failure and ultimately to myocardial infarction and stroke, which
are the leading causes of death and morbidity in developed countries [1].
The link between chronic sympathetic hyperactivity and drug-resistant HTN is well known
for several years, and is the rationale behind the development of catheter-based sympathetic
renal denervation (RDN). This treatment approach for drug resistant HTN had very promising
results in early non-blinded studies [2,3]. Recently, the lack of positive results on a randomized
sham-controlled trial raised doubts on the efficacy and patient selection for this procedure, rein-
forcing the need for further research in this field [4]. Sympathetic drive is also implicated in the
development of left ventricular hypertrophy (LVH) [5,6], but little is known about the impact of
RDN in left ventricular performance. The aim of the present study was to evaluate the effects of
RDN on LV structure and function (systolic and diastolic) in patients with resistant HTN.
Methods
Study design and population
From a single centre prospective registry including 65 consecutive patients with resistant HTN
submitted to RDN between July-2011 and April-2015, 31 patients with baseline and 1-year fol-
low-up 24h ABPM and transthoracic echocardiogram were included in this analysis. As per
protocol, all patients underwent a comprehensive transthoracic echocardiogram (TTE) at base-
line and at 1-year after RDN. The inclusion, exclusion criteria and clinical feature regarding
this registry were previously reported [7]. The research was approved by the Ethics committee
of Hospital de Santa Cruz and Nova Medical School, Lisbon, Portugal. Written informed con-
sent was collected for all the patients. Study design is summarized in Fig 1.
In summary, the patients selected had to be older than 18 years, with an office systolic blood
pressure (SBP) above 160mHg while receiving a stable antihypertensive regimen involving at
least three drugs (including a diuretic). Before RDN, during pre-scheduled visits at the outpa-
tient clinic for a period not less than 6 weeks, secondary causes for HTN were excluded, com-
pliance to medical treatment was assured and drug therapy was adjusted until maximal
tolerated regimens. Only then, if target BP values were not obtained, patients were considered
for RDN. Anatomical criteria were adopted from Symplicity trials.[2,8] Demographic variables,
clinical characteristics, anthropometric data, laboratory values, drug treatment and procedure
details were recorded and stored in a dedicated database. Creatinine clearance was calculated
using MDRD formula.[9]
Blood pressure measurement and definition of responders
Office BP readings were taken in a seated position with an oscillometric semiautomatic sphyg-
momanometer Omron HEM-907 monitor (Omron Healthcare, USA) after 5 min of rest
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according to the European Guidelines for the management of arterial hypertension [10] At
baseline, BP was measured in both arms and the arm with the higher BP was used for all subse-
quent readings. Averages of the triplicate measures were calculated and used for analysis.
Twenty-four hours ambulatory blood pressure measurements (ABPM) were taken with an
ABMmonitor (Spacelabs Healthcare, USA), according to the current European Society of
Hypertension guidelines[10].
Blood pressure responders to RDN treatment were defined as those who had a reduction in
office SBP of10 mmHg at one year follow-up or a reduction of 2mmHg in ABPM 24 hours
SBP according to Symplicity HTN3 trial design[11].
Renal denervation procedure
We have previously reported the details of the RDN procedure in our center [12]. Briefly, all
procedures were performed under mild anaesthesia for sedation and pain control (propofol
and remifentanil in weight-adjusted doses). Anticoagulation with unfractionated heparin was
used in order to obtain an activated clotting time between 250–300 seconds. After gaining fem-
oral artery access in all cases except one (where the radial artery was used), abdominal aortog-
raphy and selective renal artery angiograms were performed to confirm anatomic eligibility. At
the end, in cases with femoral access, the site was closed using a sealing device (Angio-Seal1
-St. Jude Medical, USA).
RDN was performed using the Symplicity1 (n = 25), the EnligHTN1 (n = 4), OneShot1
(n = 2) catheter using the standard technique, as previously reported [7,12,13].
Transthoracic echocardiography
Comprehensive two-dimensional and Doppler transthoracic echocardiographic studies were
performed at baseline and at 1-year follow-up in all patients, using VIVID 7 ultrasound system
(General Electric Heathcare). All echocardiographic recordings were stored in digital format
Fig 1. Flowchart with patient selection. From the total number of patients evaluated in a dedicated
outpatient hypertension clinic (n = 318), 65 patients were submitted to renal denervation, after the exclusion
of 253 due to several reasons listed. From these 65 patients, it was possible to obtain complete 1 year follow
up with ambulatory blood pressure measurement and transthoracic echocardiogram. RDN—renal
denervation; HTN—hypertension; eGFR—estimated glomerular filtration rate; ABPM –24 hours ambulatory
blood pressure measurement; TTE-transthoracic echocardiogram.
doi:10.1371/journal.pone.0149855.g001
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on a dedicated workstation for off-line subsequent analysis. The exams were performed by one
of two experienced operators (EH and MJA), while analysed and interpreted by the non-per-
former operator, both blinded to patients’ clinical, BP status and sequence of images.
Left ventricular size was evaluated by both linear (using M-mode 2D guided diameters
obtained perpendicular to the LV long axis) and volumetric (using the biplane method of disks
summation from tracings of the blood-tissue interface in the apical four- and two-chamber
views), according to accepted recommendations from the American Society of Echocardiogra-
phy and the European Association of Cardiovascular Imaging [14]. LV ejection fraction was
calculated using the following formula: EF = (EDV − ESV)/EDV, with LV volume estimates
obtained by the biplane method of disks.
Assessment of LV mass (LVM) was performed by the linear method using the cube formula
(LV mass = 0.8  1.04  [(IVS + LVID + PWT)3 −LVID3]+0.6g), with 2D guided M-mode mea-
surements obtained at end-diastole from the parasternal approach perpendicular to the LV
long axis measured at the level of the mitral valve leaflet tips. LV hypertrophy was considered
present when LV mass exceeded 115 g/m2 for men and 95 g/m2 for women.
We also calculated the relative wall thickness (RWT) measured as twice the posterior wall
thickness divided by left ventricular end-diastolic diameter, and determined the LV anatomical
pattern in each participant. Normal LVM and RWT were defined as normal LV anatomy, nor-
mal LVM and RWT>0.42 as concentric LV remodeling, increased LVM and RWT>0.42 as
concentric LVH and increased LVM in the presence of RWT<0.42 as eccentric LVH [15]. Left
atrial (LA) volume measurement was done using the disk summation algorithm similar to that
used to measure LV volume, when the LA chamber was at its greatest dimension (end of LV
systole).
LV diastolic function was assessed by pulsed-wave Doppler examination of mitral inflow
and Doppler tissue imaging of the mitral annulus. Peak velocities of early (E) and late (A)
trans-mitral flow and deceleration time (DT) were determined, and the ratio E/A was calcu-
lated. Doppler tissue imaging with pulsed-wave Doppler at the level of septal and lateral mitral
annulus was used to measure e’ velocities. The average of septal and lateral mitral annulus e’
peak velocities, were used to calculate the E/e’ ratio. The Valsalva maneuver was performed to
distinguish normal from pseudo-normal patterns. Spectral recordings were obtained at a sweep
speed of 100 mm/s at end-expiration, and each measurement was averaged over multiple car-
diac cycles to account for inter-beat variability.
Grade 1 diastolic dysfunction (impaired relaxation) was defined by the presence of an E/A
ratio<0.8, a deceleration time>200 ms and E/e0 ratio<8 in the presence of an enlarged left
atrium. Moderate (pseudo-normal, grade 2) diastolic dysfunction was defined as a mitral E/A
ratio>0.8 and<1.5 that decreases by 50% during the Valsalva maneuver, E/e’ ratio 9 to 12 and
e’<8 cm/s. Finally, severe (grade 3) diastolic dysfunction corresponds to restrictive LV filling
defined by E/A ratio>2, DT<160 ms, and average E/e’>13. All subjects with impaired LV
relaxation, pseudo-normal or restrictive filling patterns were defined as having LVDD [16].
Statistical analyses
Continuous variables are reported as mean ± standard deviation. Normality was tested with
the Kolmogorov-Smirnov test and/or Q-Q Plot visual assessment. Normally distributed vari-
ables were compared between baseline and one year follow-up using a paired Student t test or a
Wilcoxon matched-pairs test if not normally distributed. Discrete variables are expressed as
frequencies and percentages (in brackets). Statistical comparisons of baseline characteristics
and at follow-up were performed using the chi-square test or Fisher’s exact test, when appro-
priate, for categorical variables and the paired t-Student’s test or the Saterwate test for
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continuous variables. A two-tailed p value<0.05 is considered as statistically significant. Linear
regression analyses were used to calculate the correlation between the change in blood pressure
and the change in echocardiographic parameters. SPSS, Statistical Package for the Social Sci-




From the total number of patients evaluated in a dedicated outpatient hypertension clinic
(n = 318), 65 patients were submitted to renal denervation, after the exclusion of 253 due to
several reasons (listed in Fig 1). From these 65, it was possible to obtain complete 1 year follow
up with ambulatory blood pressure measurement and transthoracic echocardiogram in 31
patients that were the final population included in this analysis. Mean age was 65±7 years, 48%
were males (n = 15), and all were caucasians. Concerning traditional cardiovascular risk fac-
tors, obesity was present in 68% of the patients (mean body mass index 32±6 Kg/m2), type 2
diabetes in 71%, dyslipidaemia in 68% and active smoking in one patient (3.2%). Coronary
artery disease was present in 10 patients (32%) and any vascular disease in 11 (36%). Estimated
mean glomerular filtration rate was 76±25mL/min/1.73m2, with five patients having chronic
kidney disease, defined as eGFR<60 ml/min/1.73 m2. Baseline characteristics are shown in
Table 1.
Table 1. Patient’s baseline and RDN procedure characteristics.
Demographic and clinical variables
Age (years) 65±7
Male (%) 15 (48.4)




Obesity (%) 21 (67.7)
Atrial fibrillation (%) 1 (3.2)
Previous stroke (%) 2 (6.5)
Type 2 Diabetes (%) 22 (71)
Dyslipidaemia (%) 21 (67.7)
Smoking (%) 1 (3.2)
Sleep apnea (%) 5 (19.1)
eGFR (ml/min/1,73m2) 76.4±24.7
CKD* (%) 5 (16.1)
Hypertension > 10 years (%) 28 (90.3)
Coronary artery disease (%) 10 (32.3)
Any vascular disease (%) 11 (35.5)
RDN Procedure
Mean number of applications right renal artery 5.1±1.3
Mean number of applications left renal artery 5.7±1.1
Mean number of applications per patient 10.8±2.3
eGFR, estimated glomerular filtration rate;
CKD, *Chronic kidney disease(eGFR <60 ml/min/1,73m2)
doi:10.1371/journal.pone.0149855.t001
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The majority of patients (90%) had hypertension lasting for more than 10 years, treated
with a median of 5.8 anti-hypertensive agents from a median of 5.5 different pharmacological
classes. Almost all patients were treated with calcium antagonists, 96.8% (n = 30), 87% with
diuretics, 74% with spironolactone, 61% with ACE inhibitors, 61% with ARB inhibitors, 84%
with beta-blockers and 71% with a sympatholytic drug. (Table 2)
Blood pressure control by RDN
At baseline, mean office SBP and diastolic blood pressure (DBP) were 176±24 mmHg and 90
±14 mmHg, respectively, and mean heart rate was 73±11 bpm. The 24-hour ABPM showed
the following average values: SBP 150±20 mmHg, DBP 83±10 mmHg, pulse pressure 67
±18mmHg (Table 3).
Overall, at one-year follow-up, there was a significant reduction in both office SBP (176±24
to 149±13mmHg, p<0.001) and DBP (90±14 to 79±11mmHg, p<0.001). On 24-hour ABPM,
there was a significant drop on: SBP (150±20 to 132±14 mmHg, p<0.001, mean decrease of 18
mmHg), on DBP (83±10 to 74±9 mmHg, average decrease of 9 mmHg, p<0.01) and on pulse
pressure from 67±18 to 58±13 mmHg, p = 0.001, a mean decrease of 5 mmHg (Fig 2).
This was found in spite of the significant reduction in the number of both antihypertensive
drugs and classes in use at 1-year: 5.8±1.1 to 5.0±1.2 (p = 0.002) and 5.5±0.9 to 4.9±1.1
(p = 0.015) respectively.
At 1-year follow-up, 22 of patients (71%) were considered office SBP responders and 26
(84%) ABPM SBP responders based on a drop of more than 10mmHg on office SBP and
2mmHg on 24 hours ABPM SBP.
Echocardiographic parameters
Transthoracic echocardiography at baseline revealed LV hypertrophy in 27 patients (87%),
with a mean LV mass of 152±32 g/m2. Distribution among different geometric patterns is
shown in Fig 3. The large majority had concentric hypertrophy (74%), with only 3% presenting
a normal pattern. All patients had a preserved EF (>55% by Simpson’s biplane method), with a
mean LVEF of 65±9%. Mean LA volume was 33±8mL/m2, and 48.4% had 34ml/ m2.
LVDD was diagnosed in 29 (93.5%) patients, 11 (37.9%) of them had grade 1 diastolic dys-
function, 18 patients a pseudo-normal pattern (62.1%); 2 patients were in atrial fibrillation and
Table 2. Antihypertensive medication.
Baseline One year p
Mean number of antihypertensive drugs 5.8±1.1 5.0±1.2 0.002
Mean number of classes 5.5±0.9 4.9±1.1 0.015
ACE inhibitors 19 (61.3) 17(54.8) 0.688
ARBs (%) 19 (61.3) 18 (58.1) 1.0
Beta-blockers (%) 26 (83.9) 27 (87.1) 1.0
Calcium channel blockers (%) 30 (96.8) 21 (67.7) 0.012
Diuretics (%) 27 (87.1) 24 (77.4) 0.727
Spironolactone (%) 23 (74.2) 26 (83.9) 0.453
Sympatholytic (%) 22 (71) 19 (61.3) 0.508
Aliskirene 4 (12.9) 0 0.046
ACE, Angiotensin converting enzyme; ARB, Angiotensin receptor blockers
doi:10.1371/journal.pone.0149855.t002
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there were no patients with a restrictive filling pattern (Fig 4). For the entire population, E/A
ratio was 0.8±0.2, E-wave deceleration time 225±49ms and E/e’ ratio 11±3.
After one-year, there was an overall significant reduction in LVmass (152±32 to 136±34g/m2,
p<0.001—Fig 2), an increase in mitral valve deceleration time (from 225±49ms to 247±51ms,
p = 0.015—Table 4). There were no significant changes in the distribution of patients among the
different LV geometric patterns (Fig 3) or in the percentage of patients in each diastolic function
group (Fig 4) from baseline to 1 year after renal denervation.
Relation between blood pressure reduction and echocardiographic
findings
Reduction in LV mass reached statistical significance in ABPM SBP responders (n = 26): 148
±32 to 133±29g/m2, p<0.001. In non-responders (n = 5), LV mass also decreased: 166±23 to
129±15g/m2, p = 0.05, although not reaching statistical significance certainly due to sample
Table 3. RDN results on blood pressure and heart rate.
Baseline One-year P
Office systolic BP (mmHg) 176±24 149±13 < .001
Office diastolic BP (mmHg) 90±14 79±11 < .001
Heart rate (bpm) 73±11 70±11 .261
ABPM systolic BP (mmHg) 150±20 132±14 < .001
ABPM diastolic BP (mmHg) 83±10 74±9 < .001
ABPM pulse pressure (mmHg) 67±18 58±13 .001
ABPM mean pressure (mmHg) 105±9 95,3±8,4 < .001
ABPM heart rate (bpm) 67.6±9.1 65.5±9.5 .090
ABPM SBP responders* (%) - 26 (83.9) -
Office SBP responders** (%) - 22 (71) -
BP, blood pressure; bpm, beats per minute; ABPM, 24 hours ambulatory blood pressure measurement;
* ABPM SBP responders: a decrease of 2mmHg between baseline ABPM SBP and at one year;
**Office SBP responders: a decrease of 10mmHg between baseline office SBP and at one year.
doi:10.1371/journal.pone.0149855.t003
Fig 2. Results at 1 year after renal denervation (blood pressure and left ventricle mass index). Results
in systolic blood pressure (both office and ABPM) and LVMI in TTE at 1-year follow-up are shown, with
significant reductions in both parameters. BP- blood pressure; ABPM –24 hours ambulatory blood pressure
measurement; LVMI—left ventricle mass index; TTE-transthoracic echocardiogram.
doi:10.1371/journal.pone.0149855.g002
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size. From the scatter-plot graphic (Fig 5) where the relationship between LV mass and ABPM
SBP changes at one year for the entire population is shown, we observe that changes in SBP
and LV mass are not correlated, as depicted by the very low r2 values obtained.
Safety
There were 3 mild hematomas and 1 femoral pseudoaneurysm, treated with surgery without
any permanent sequelae. There were no complications related to the renal arteries, namely dis-
section or perforation.
Discussion
The main findings of our study were: 1) Renal denervation in patients with resistant HTN was
associated with significant reduction in both office and ABPM blood pressure at 1 year follow-
Fig 3. Comparison of different LV geometric patterns at baseline and 1 year after renal denervation.
The percentage of patients in each LV geometric pattern class is depicted. Concentric remodelling was
defined as relative wall thickness (RWT) of >0.42 with normal LV mass and normal geometry was defined as
a RWT of0.42 with normal LV mass.
doi:10.1371/journal.pone.0149855.g003
Fig 4. Comparison of LV diastolic function at baseline and 1 year after renal denervation. The
percentage of patients in each diastolic function group (Normal, Impaired relaxation, pseudonormal and
restrictive) is depicted.
doi:10.1371/journal.pone.0149855.g004
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LVEDV (mL) 93.3±18,2 110.9±27.4 .004
LVESV (mL) 35.8±12.6 38.2±3.1 .121
IVSTd (mm) 13.4±1.9 13.1±2.4 .616
PWTd (mm) 11.7±1.6 11.8±1.7 .620
LVEDD (mm) 48.7±5.8 47.8±5.4 .230
LVESD (mm) 28.9±5.7 27.9±6.5 .296
LV mass/BSC (g/m2) 152.3±32.4 135.7±33.9 < .001
LA volume index (ml/m2) 32.8±8.3 34.1±6.2 .227
Function
LVEF Simpson (%) 64.5±9.2 67.7±9.1 .001
Stroke volume (ml) 81.7±14.9 102.7±16.7 .075
Mitral valve E Vmax (cm/s) 73.6±15.2 73.2±16.4 .881
Mitral valve A Vmax (cm/s) 88.3±16.5 86.0±21 .469
Mitral valve E/A ratio 0.84±0.21 0.86±0.20 .574
Mitral valve E deceleration time (ms) 224.9±49.4 247.3±50.5 .015
Mitral valve lateral E’ (cm/s) 7.2±1.8 7.3±2.1 .417
Mitral valve lateral E/E’ 11.0±3.3 10.5±3.5 .228
LVEDVI, left ventricle end-diastolic volume; LVESVI, left ventricle end-systolic volume; IVSTd,
interventricular septum thickness on diastole; PWTd, posterior wall thickness on diastole; LVEDD, left
ventricle end-diastolic diameter, LVESD, left ventricle end-systolic diameter; LV, left ventricle; BSC, body
surface area; LA, left atrium; LVEF, left ventricle ejection fraction.
doi:10.1371/journal.pone.0149855.t004
Fig 5. Relation between LVmass index and ABPM systolic BP changes at 1 year follow-up. Horizontal
line set at 2mmHg for responder in ABPM systolic BP reduction. Five patients had regression in LVMI without
significant (>2mmHg) reduction in ABPM systolic BP and 5 additional patients were ABPM systolic BP
responders but without reduction in LVMI. BP- blood pressure; ABPM –24 hours ambulatory blood pressure
measurement; LV—left ventricle.
doi:10.1371/journal.pone.0149855.g005
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up; 2) There was a significant reduction in left ventricle mass index, a recognized marker of
HTN target organ damage.
Renal denervation has been associated with significant reductions in both office and ABPM
blood pressure in many trials[2,3,17] and registries[18]. In a recent large randomized trial the
reductions in systolic blood pressure, the primary endpoint of the trial, was not significant as
compared to a sham control arm, in striking contrast with previous trial.[4] Many possible
confounding factors were pointed out that could explain these apparent contradictory findings,
[19] but most importantly these inconsistent results of renal denervation makes a strong case
for additional studies looking beyond blood pressure measurements. With this rational we
sought to evaluate the impact of renal denervation in left ventricle hypertrophy, which is one of
the most important markers of target organ damage of HTN and has been associated with an
increased rate of cardiovascular events and death independent of BP values[20–22]. At 1 year
after renal denervation, there was a significant reduction in left ventricle mass and our results
are in line with previous studies using both transthoracic echocardiogram [23,24] and cardiac
magnetic resonance [25].
Brandt MC et al[24] in a study including 46 patients, found that renal denervation was asso-
ciated with a significant reduction in LV mass index and filling and improvements in mitral
valve lateral E/E´, indicator of LV filling pressure in transthoracic echocardiogram. In another
small study using similar methodology, Schirmer SH et al [23] evaluated the impact of renal
denervation in left ventricle hypertrophy by echocardiogram and were able to document that
in patients with resistant HTN, the observed reductions in LV mass were similar across tertiles
of systolic blood pressure, suggesting that the pathophysiology could be related also to a direct
effect of sympathetic hyperactivity, not dependent on blood pressure or heart rate. In our regis-
try we didn´t found a correlation between LV mass and ABPM SBP changes at one year (Fig
5), which suggests that LV hypertrophy reduction, after RDN, might be affected by other
mechanisms beyond BP reduction. This is not new in the field of HTN and it has been previ-
ously described that for similar BP reduction, different pharmacological agents could lead to
different impact on LV hypertrophy [26]. In one interesting study, a greater regression in LV
hypertrophy was documented for a drug combination that targeted neuroendocrine activity
(both renin-angiotensine-aldosterone system and sympathetic nervous system), for the same
magnitude of BP reduction [27]. Regarding the pathophysiological mechanism of the observed
reduction of LV mass, it could be the result not only of a reduction in myocyte hypertrophy
but also of absolute collagen content and diffuse interstitial myocardial fibrosis, as was sug-
gested in a recent cardiac MRI study [28].
In a multicenter study including 72 patients and using cardiac magnetic resonance imaging,
Mahfoud F et al [25] also demonstrated that at 6 months follow-up renal denervation was asso-
ciated with a significant reduction in left ventricle mass index, an improvement in ejection frac-
tion and a reduction in left ventricle circumferential strain, a surrogate of diastolic function.
Taken together these studies are consistent in regression of LV mass and improvement in sev-
eral markers of diastolic function. In our study, we also found a significant reduction in LV
mass but there were no significant changes in transthoracic echocardiogram parameters of dia-
stolic function. In addition, we didn’t found any reduction in left atrial volume index. There
was a small but significant increase in LV ejection fraction and LV end-diastolic volume, which
could be explained at least partially by the numerically lower heart rate at 1 year follow-up doc-
umented both on office and on the average 24-hour heart rate from the ABPM recording. This
small increase in EF is in line with some [24,25] but not all of the previous studies [23].
Some additional particular features of the present study should also be taken in consider-
ation. First, our results come from a registry with a very rigorous selection process of patients
for renal denervation, perceived from the high mean number (5.8) of antihypertensive drugs,
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the baseline office and ABPM blood values and the patient selection flowchart presented in Fig
1, with an almost 5:1 proportion of patients evaluated/treated (only 65 patients submitted to
RDN out of the 318 with resistant HTN evaluated in our outpatient clinic). It is also worth
mentioning that an average of 5.8 drugs is higher than that reported by other similar studies
evaluating the impact of RDN on LV mass (ranging from 4.3 in the study of Schirmer SH et al
[23] to 4.7 in the study of Brandt MC et al [24]. Secondly, in our study we have a very high per-
centage of patients taking spironolactone on baseline (74%). This high aldosterone antagonist
use is in line with the described strict selection process, and in addition it might have also con-
tributed to explain the positive results after renal denervation, since it has been demonstrated
that patients previously treated with spironolactone where better responders to this procedure.
[4,19] Thirdly, we used 24-hour ABPM in all patients and this is considered to be a more accu-
rate evaluation of the impact of treatment on blood pressure.[10] Lastly, our results both in
blood pressure and LV mass were evaluated at 1 year, a significantly longer follow up than that
reported by the previous studies that evaluated patients at 6 months follow up.[23–25]
Limitations
The present study has several limitations that should be acknowledged: 1) It is a single centre
prospective registry with a small sample size. 2) The lack of a control group and the fact that
there was no blinding either for RDN (sham not performed) or for the physicians performing
the follow-up echocardiograms; 3) There were changes on antihypertensive drug therapy dur-
ing the clinical follow-up which can influence the reductions in blood pressure and LV mass,
although in our study the mean number of drugs was reduced. This way, the reduction
obtained with renal denervation could have been underestimated in this real world setting; 4)
No specific techniques were used to control for patient adherence to medication; 5) Echocar-
diograms were not reviewed in a core lab, which could potentially be associated with less repro-
ducible measurements; 6) Cardiac MRI was not used and could have provided a more accurate
evaluation of LV mass changes.
Conclusions
In this single centre registry of patients with resistant hypertension, renal denervation was
associated with significant reduction in both office and 24h-ABPM blood pressure, and a sig-
nificant decrease in left ventricle mass evaluated by transthoracic echocardiogram at 1 year fol-
low-up. There were no significant changes in left atrium volume index or in the distribution of
patients among the different left ventricle geometric patterns and diastolic function subgroups.
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